CO2018004684A2 - Métodos para tratar la epilepsia - Google Patents

Métodos para tratar la epilepsia

Info

Publication number
CO2018004684A2
CO2018004684A2 CONC2018/0004684A CO2018004684A CO2018004684A2 CO 2018004684 A2 CO2018004684 A2 CO 2018004684A2 CO 2018004684 A CO2018004684 A CO 2018004684A CO 2018004684 A2 CO2018004684 A2 CO 2018004684A2
Authority
CO
Colombia
Prior art keywords
methods
nonsense mutation
treat epilepsy
epileptic disease
treating
Prior art date
Application number
CONC2018/0004684A
Other languages
English (en)
Inventor
Ellen Welch
Yuki Tomizawa
Priya Vazirani
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CO2018004684A2 publication Critical patent/CO2018004684A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Métodos para tratar, prevenir, mejorar o controlar una enfermedad epiléptica mediada por mutación sin sentido, que comprende administrar un ácido 1,2,4-oxadiazolbenzoico a un paciente que tiene una enfermedad epiléptica mediada por mutación sin sentido. En particular, métodos para tratar, prevenir, mejorar o controlar una enfermedad epiléptica mediada por mutación sin sentido en CDKL5 y/o SCN1A (síndrome de Dravet).
CONC2018/0004684A 2015-10-30 2018-04-30 Métodos para tratar la epilepsia CO2018004684A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248891P 2015-10-30 2015-10-30
PCT/US2016/059262 WO2017075312A1 (en) 2015-10-30 2016-10-28 Methods for treating epilepsy

Publications (1)

Publication Number Publication Date
CO2018004684A2 true CO2018004684A2 (es) 2018-08-10

Family

ID=58632013

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004684A CO2018004684A2 (es) 2015-10-30 2018-04-30 Métodos para tratar la epilepsia

Country Status (15)

Country Link
US (2) US10517853B2 (es)
EP (1) EP3368042A4 (es)
JP (1) JP2018531975A (es)
KR (1) KR20180081516A (es)
CN (1) CN108348527A (es)
AR (1) AR106530A1 (es)
BR (1) BR112018008838A8 (es)
CA (1) CA3003132A1 (es)
CO (1) CO2018004684A2 (es)
HK (1) HK1251965A1 (es)
IL (1) IL258988A (es)
MX (1) MX2018005361A (es)
PH (1) PH12018500885A1 (es)
TW (1) TW201729807A (es)
WO (1) WO2017075312A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
EP3390636B1 (en) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense oligomers for treatment of dravet syndrome
PT3673080T (pt) 2017-08-25 2023-12-06 Stoke Therapeutics Inc Oligómeros anti-sentido para o tratamento de estados patológicos e outras doenças
US11301527B2 (en) 2019-05-06 2022-04-12 Acto Technologies Inc. Event-driven content recommendation engine
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
TW202146392A (zh) * 2020-03-17 2021-12-16 日商大日本住友製藥股份有限公司 㗁二唑衍生物
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (es) 1962-04-17
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
CZ66498A3 (cs) 1995-09-07 1998-07-15 Novartis Ag Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití
WO1997041105A1 (fr) 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Nouveaux derives de benzene a substitution heterocycle et herbicides
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
AU744259B2 (en) 1997-04-07 2002-02-21 Gian Luca Araldi Analogs of cocaine
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
WO1999021852A1 (fr) 1997-10-27 1999-05-06 Nippon Soda Co., Ltd. Nouveaux derives de benzoylpyrazole et herbicides
NZ507696A (en) 1998-04-23 2003-10-31 Cortech Inc Triazole, oxadiazole and thiadiazole derivatives useful as cysteine protease inhibitors
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
JP2002533397A (ja) 1998-12-23 2002-10-08 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
WO2000058280A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
AU3196100A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
ES2250128T3 (es) 1999-05-17 2006-04-16 Novo Nordisk A/S Antagonistas/agonistas inversos de glucagon.
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU2001248765A1 (en) 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
BR0111206A (pt) 2000-05-22 2003-04-15 Aventis Pharma Inc Derivados de arilmetilamina para uso como inibidores de triptase
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US7115612B2 (en) 2001-04-19 2006-10-03 Bayer Aktiengesellschaft Arylsulfonamides as antiviral agents
CN1638776A (zh) 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004014902A2 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
EP1536790A2 (en) 2002-08-09 2005-06-08 AstraZeneca AB Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
EP1622872A1 (en) 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP1618098B1 (en) 2003-04-11 2014-11-19 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
US9051342B2 (en) 2004-10-13 2015-06-09 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
CN101193632A (zh) * 2005-04-08 2008-06-04 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
NZ562197A (en) 2005-04-08 2010-09-30 Ptc Therapeutics Inc Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
JP2008546376A (ja) * 2005-06-16 2008-12-25 バイオノミックス リミテッド Ｓｃｎ１ａ遺伝子における変異を検出することによっててんかんを診断および処置するための方法
CA2647903C (en) 2006-03-30 2016-12-13 Ptc Therapeutics, Inc. Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
WO2008030570A1 (en) 2006-09-08 2008-03-13 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
MX344418B (es) 2006-09-25 2016-12-15 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
JP2010506840A (ja) 2006-10-12 2010-03-04 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の経口的に活性な１，２，４−オキサジアゾールの投与方法
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
CA2708761C (en) 2007-12-17 2015-04-14 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
KR101273765B1 (ko) 2008-06-24 2013-06-12 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체를 조정하는 화합물 및 방법
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
CN103189060A (zh) * 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物
CN112979575A (zh) 2014-03-06 2021-06-18 Ptc医疗公司 1,2,4-噁二唑苯甲酸的药物组合物和盐
WO2015188037A1 (en) 2014-06-06 2015-12-10 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Also Published As

Publication number Publication date
AR106530A1 (es) 2018-01-24
BR112018008838A2 (pt) 2018-11-06
IL258988A (en) 2018-06-28
JP2018531975A (ja) 2018-11-01
US20200188362A1 (en) 2020-06-18
WO2017075312A1 (en) 2017-05-04
BR112018008838A8 (pt) 2019-02-26
US20180333397A1 (en) 2018-11-22
MX2018005361A (es) 2018-06-07
US10517853B2 (en) 2019-12-31
CA3003132A1 (en) 2017-05-04
EP3368042A1 (en) 2018-09-05
KR20180081516A (ko) 2018-07-16
PH12018500885A1 (en) 2018-10-29
HK1251965A1 (zh) 2019-05-10
CN108348527A (zh) 2018-07-31
TW201729807A (zh) 2017-09-01
EP3368042A4 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
CO2018004684A2 (es) Métodos para tratar la epilepsia
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
BR112017020973A2 (pt) método para tratar câncer em um paciente
PE20180260A1 (es) Metodos y kits para tratar la depresion
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112016010454A2 (pt) métodos para tratar uma taupatia
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CO7160102A2 (es) Fármaco para prevenir y/o tratar la enfermedad renal poliquística
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2019002190A (es) Uso de pridopidina para tratar distonías.
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
AR106935A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
AR102871A1 (es) Métodos de tratamiento de fibrosis